Cerevel Therapeutics (CERE) Short Interest Ratio & Short Volume → Biden out June 13; Kamala won’t replace him? (From Paradigm Press) (Ad) Free CERE Stock Alerts $42.59 -0.04 (-0.09%) (As of 05/2/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Cerevel Therapeutics Short Interest DataCurrent Short Volume7,920,000 sharesPrevious Short Volume9,620,000 sharesChange Vs. Previous Month-17.67%Dollar Volume Sold Short$330.26 millionShort Interest Ratio / Days to Cover5.7Last Record DateApril 15, 2024Outstanding Shares181,580,000 sharesFloat Size87,000,000 sharesShort Percent of Float9.10%Today's Trading Volume1,517,671 sharesAverage Trading Volume1,454,604 sharesToday's Volume Vs. Average104% Short Selling Cerevel Therapeutics ? Sign up to receive the latest short interest report for Cerevel Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCERE Short Interest Over TimeCERE Days to Cover Over TimeCERE Percentage of Float Shorted Over Time Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him Cerevel Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20247,920,000 shares $330.26 million -17.7%9.1%5.7 $41.70 3/31/20249,620,000 shares $406.64 million +38.2%11.1%6.4 $42.27 3/15/20246,960,000 shares $294.62 million -2.0%8.0%4.4 $42.33 2/29/20247,100,000 shares $291.10 million +4.7%8.2%2.6 $41.00 2/15/20246,780,000 shares $291.07 million +12.6%7.8%2.4 $42.93 1/31/20246,020,000 shares $252.24 million +43.0%7.0%2.3 $41.90 Get the Latest News and Ratings for CERE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20244,210,000 shares $179.77 million -13.7%4.9%1.6 $42.70 12/31/20234,880,000 shares $206.91 million +22.6%5.7%1.9 $42.40 12/15/20233,980,000 shares $164.37 million -48.5%4.6%1.7 $41.30 11/30/20237,720,000 shares $200.18 million -6.0%9.2%4.1 $25.93 11/15/20238,210,000 shares $198.44 million -1.6%9.7%9.4 $24.17 10/31/20238,340,000 shares $197.24 million +12.6%9.9%9.8 $23.65 10/15/20237,410,000 shares $165.76 million +9.3%10.4%8.4 $22.37 9/30/20236,780,000 shares $148.01 million +12.6%9.9%9.6 $21.83 9/15/20236,020,000 shares $136.35 million +10.7%8.8%9.1 $22.65 8/31/20235,440,000 shares $128.93 million +7.1%7.9%8.6 $23.70 8/15/20235,080,000 shares $110.54 million -1.7%7.4%8.2 $21.76 7/31/20235,170,000 shares $158.15 million -5.1%7.6%8.6 $30.59 7/15/20235,450,000 shares $164.48 million +2.3%8.0%9.9 $30.18 6/30/20235,330,000 shares $169.44 million +1.0%7.8%9.6 $31.79 6/15/20235,280,000 shares $186.81 million +5.2%7.8%9.5 $35.38 5/31/20235,020,000 shares $163.65 million +6.4%7.4%8.7 $32.60 5/15/20234,720,000 shares $151.56 million +5.8%7.0%7.1 $32.11 4/30/20234,460,000 shares $129.52 million -10.1%6.6%6.7 $29.04 4/15/20234,960,000 shares $122.56 million -6.8%7.3%8.2 $24.71 3/31/20235,320,000 shares $129.75 million +0.8%7.9%8.8 $24.39 3/15/20235,280,000 shares $129.10 million +9.5%7.8%8.4 $24.45 2/28/20234,820,000 shares $128.65 million -11.1%7.2%8 $26.69 2/15/20235,420,000 shares $180.97 million -4.9%8.1%9.5 $33.39 1/31/20235,700,000 shares $194.66 million +7.8%8.5%10.9 $34.15 1/15/20235,290,000 shares $173.46 million +7.1%7.9%9.7 $32.79 12/30/20224,940,000 shares $155.81 million +2.9%7.4%8.9 $31.54 12/15/20224,800,000 shares $122.47 million +0.2%7.2%8.5 $25.52 11/30/20224,790,000 shares $138.72 million -5.0%7.2%8.7 $28.96 11/15/20225,040,000 shares $147.92 million -10.6%7.5%8.6 $29.35 10/31/20225,640,000 shares $157.69 million +3.1%8.5%7 $27.96 10/15/20225,470,000 shares $146.27 million +0.7%8.2%6.5 $26.74 9/30/20225,430,000 shares $153.45 million -2.7%8.2%6.6 $28.26 9/15/20225,580,000 shares $166.79 million +0.7%8.4%6.7 $29.89 8/31/20225,540,000 shares $161.21 million +7.6%8.3%6.9 $29.10$5,000 Gold? (Ad)Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. CERE Short Interest - Frequently Asked Questions What is Cerevel Therapeutics' current short interest? Short interest is the volume of Cerevel Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 7,920,000 shares of CERE short. 9.10% of Cerevel Therapeutics' shares are currently sold short. Learn More on Cerevel Therapeutics' current short interest. What is a good short interest ratio for Cerevel Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CERE shares currently have a short interest ratio of 6.0. Learn More on Cerevel Therapeutics's short interest ratio. Which institutional investors are shorting Cerevel Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cerevel Therapeutics: Concourse Financial Group Securities Inc., Simplex Trading LLC, Westchester Capital Management LLC, ADAR1 Capital Management LLC, DeepCurrents Investment Group LLC, Balyasny Asset Management L.P., and Picton Mahoney Asset Management. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Cerevel Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.10% of Cerevel Therapeutics' floating shares are currently sold short. Is Cerevel Therapeutics' short interest increasing or decreasing? Cerevel Therapeutics saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 7,920,000 shares, a drop of 17.7% from the previous total of 9,620,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cerevel Therapeutics' float size? Cerevel Therapeutics currently has issued a total of 181,580,000 shares. Some of Cerevel Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cerevel Therapeutics currently has a public float of 87,000,000 shares. How does Cerevel Therapeutics' short interest compare to its competitors? 9.10% of Cerevel Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Cerevel Therapeutics: Legend Biotech Co. (6.04%), Ascendis Pharma A/S (6.18%), Jazz Pharmaceuticals plc (6.14%), Intra-Cellular Therapies, Inc. (3.71%), Viking Therapeutics, Inc. (10.11%), Roivant Sciences Ltd. (8.18%), Elanco Animal Health Incorporated (3.14%), Cytokinetics, Incorporated (13.91%), Ionis Pharmaceuticals, Inc. (7.12%), Blueprint Medicines Co. (6.94%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Cerevel Therapeutics stock? Short selling CERE is an investing strategy that aims to generate trading profit from Cerevel Therapeutics as its price is falling. CERE shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cerevel Therapeutics? A short squeeze for Cerevel Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CERE, which in turn drives the price of the stock up even further. How often is Cerevel Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CERE, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Legend Biotech Short Interest Data Ascendis Pharma A/S Short Interest Data Jazz Pharmaceuticals Short Interest Data Intra-Cellular Therapies Short Interest Data Viking Therapeutics Short Interest Data Roivant Sciences Short Interest Data Elanco Animal Health Short Interest Data Cytokinetics Short Interest Data Ionis Pharmaceuticals Short Interest Data Blueprint Medicines Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CERE) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingYour bank is lying to you.MyBankTrackerA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchTrump just won 2024Porter & Company